A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
08/2006
08/24/2006	WO2006089150A2 Antiangiogenic agents with aldesleukin
08/24/2006	WO2006089064A1 Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody
08/24/2006	WO2006088949A1 Fused heterocyclic compounds useful as inhibitors of histone deacetylase
08/24/2006	WO2006088219A1 Il-13 production inhibitor
08/24/2006	WO2006088193A1 Anti-tumor agent
08/24/2006	WO2006088080A1 CYCLOHEPTA[b]PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME
08/24/2006	WO2006088017A1 Sugar chain containing 4-position halogenated galactose and application thereof
08/24/2006	WO2006087759A2 Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field
08/24/2006	WO2006087756A2 Poly-epitope peptide derived from thymidylate synthase having immunological and anti-tumour activity
08/24/2006	WO2006087637A2 Anti her2/neu antibody
08/24/2006	WO2006087538A1 Chemical compounds
08/24/2006	WO2006087530A1 Chemical compounds
08/24/2006	WO2006087400A1 Cytotoxic activity of the ethyl acetate fraction of an extract obtained from viscum cruciatum sieber
08/24/2006	WO2006087229A1 Substituted pyrido (2 , 3-d) pyrimidine derivatives useful as medicines for the treatment of autoimmune disorders
08/24/2006	WO2006087145A1 Device and method for identifying mycotoxins
08/24/2006	WO2006087077A2 Hsp90-inhibiting triazole derivatives
08/24/2006	WO2006086978A2 Use of deuterated n-[2-(5-methoxy-1h-indol-3-yl)-ethyl]acetamides and the pharmaceutically acceptable salts thereof, and medicaments containing said compounds
08/24/2006	WO2006086891A1 Insulin-like growth factor binding protein-4 compounds and methods for inhibiting angiogenesis and tumor growth in mammalian cells
08/24/2006	WO2006086822A1 A molecule and chimeric molecules thereof
08/24/2006	WO2006076387A3 Cyanidin-3-glucoside as an anti-neoplastic agent
08/24/2006	WO2006071644A8 Selective inhibitors of erk protein kinases and uses therof
08/24/2006	WO2006070195A8 Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
08/24/2006	WO2006067635A3 USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
08/24/2006	WO2006065686A3 Spiro derivatives as lipoxygenase inhibitors
08/24/2006	WO2006060419A3 Biomarkers for pre-selection of patients for anti-igf1r therapy
08/24/2006	WO2006055638A3 Fully human monoclonal antibodies to il-13
08/24/2006	WO2006043079A3 Compositions and methods for the control of mammary cell number
08/24/2006	WO2006039545A3 Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
08/24/2006	WO2006034113A3 Quinolone analogs as cell proliferation inhibitors
08/24/2006	WO2006025991A3 Isoindoline compounds and methods of making and using the same
08/24/2006	WO2006018723A3 Androgen modulators
08/24/2006	WO2006013388A3 Materials and methods for modulating signalling by alpha-v integrin molecules
08/24/2006	WO2006005142A3 Mono- and polycyclic compounds with therapeutic activity, pharmaceutical compositions including them and intermediates for making them
08/24/2006	WO2005065709A3 Lyophilized antibody conjugate formulation
08/24/2006	US20060191027 Cystine-knot polypeptides: Cloaked-2 molecules and uses thereof
08/24/2006	US20060191024 Method for preparing anti-MIF antibodies
08/24/2006	US20060189692 Novel anti-proliferative pharmaceutical composition
08/24/2006	US20060189691 Use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person
08/24/2006	US20060189687 decreased toxicity; for cytolysis of tumors; gene therapy; immunotherapy
08/24/2006	US20060189674 Deacetylase inhibitors
08/24/2006	US20060189673 Phenylazole compound, production process therefor and antioxidant
08/24/2006	US20060189671 Compounds, compositions, and methods
08/24/2006	US20060189656 Piperidine derivatives and agent comprising the derivative as active ingredient
08/24/2006	US20060189647 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof
08/24/2006	US20060189637 Anilinoquinazaolines as protein tyrosine kianse inhibitors
08/24/2006	US20060189632 MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine
08/24/2006	US20060189631 Substituted imidazopyrimidines for the prevention and treatment of cancer
08/24/2006	US20060189630 Mitotic kinesin inhibitors
08/24/2006	US20060189629 N-(2-morpholin-4-ylethyl)-1-(4-{[4-(trifluoromethoxy)benzyl]oxy}phenyl)-1H -benzimidazole-5-carboxamide; c-Kit proto-oncogene (stem cell factor receptor) anhibitor; tyrosine kinase inhibitor; antiproliferative, anticarcinogenic agent;
08/24/2006	US20060189625 Cyclic aminophenyl sulfamate derivative
08/24/2006	US20060189609 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders
08/24/2006	US20060189598 substituted azole acid derivatives which modulate blood glucose levels, triglyceride levels, insulin levels and non-esterified fatty acid levels; hypolipidemic agent; hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity, atherosclerosis; Type 2 diabetes
08/24/2006	US20060189578 Method for the synthesis of compounds of formula I and their uses thereof
08/24/2006	US20060189576 Substituted vitamin d analogues and their therapeutic uses
08/24/2006	US20060189567 Compound having affinity with calcified tissue
08/24/2006	US20060189563 Detection and modulation of IAPS and NAIP for the diagnosis and treatment of proliferative disease
08/24/2006	US20060189558 Delivery of substances to cells
08/24/2006	US20060189550 Immunostimulatory, Covalently lipidated oligonucleotides
08/24/2006	US20060189544 Integrin-Mediated drug targeting
08/24/2006	US20060189525 DADD, death activator death domain protein
08/24/2006	US20060189521 Human Liver Regeneration Associated Protein and the Use Thereof
08/24/2006	US20060189518 Preventing/remedies for cancer
08/24/2006	US20060189483 Metal-containing compositions, preparations and uses
08/24/2006	US20060188990 Novel prostate tumor-specific promoter
08/24/2006	US20060188913 Methods and products for enhancing immune responses using imidazoquinoline compounds
08/24/2006	US20060188563 Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
08/24/2006	US20060188560 Delivery system for nucleic acids
08/24/2006	US20060188534 Dispersions for the formulation of slightly or poorly soluble agents
08/24/2006	US20060188522 Viral agents
08/24/2006	US20060188497 Immunotherapeutic combination for the treatment of tumors that over-express receptors with tyrosine kinase activity
08/24/2006	US20060188484 Virus vectors and methods of making and administering the same
08/24/2006	US20060188483 Virus vectors and methods of making and administering the same
08/24/2006	US20060188480 Viral vectors
08/24/2006	US20060188479 Plasmid for tissue targeted treatment of tumors; antitumor agents
08/24/2006	US20060188477 Use of interferon alpha 5 in the treatment of viral liver diseases
08/24/2006	US20060188472 HAS-active ingredient conjugates
08/24/2006	US20060188437 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
08/24/2006	DE102005008309A1 Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone Pharmaceutical preparations containing fluoroalkyl-containing metal complexes and epothilones
08/24/2006	DE102005007304A1 Triazolderivate Triazole derivatives
08/24/2006	DE102005006388A1 Replikationsdefiziente RNA-Viren als Impfstoffe Replication-deficient RNA viruses as vaccines
08/24/2006	CA2599566A1 Insulin-like growth factor binding protein-4 compounds and methods for inhibiting angiogenesis and tumor growth in mammalian cells
08/24/2006	CA2599046A1 Antitumor agent
08/24/2006	CA2598988A1 Cyclohepta[b]pyridine-3-carbonylguanidine derivative and pharmaceutical product containing the same as nhe inhibitors
08/24/2006	CA2598535A1 Anti her2/neu antibody
08/24/2006	CA2598465A1 Substituted pyrido (2 , 3-d) pyrimidine derivatives useful as medicines for the treatment of autoimmune disorders
08/24/2006	CA2598454A1 Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
08/24/2006	CA2598448A1 Antiangiogenic agents with aldesleukin
08/24/2006	CA2598292A1 Poly-epitope peptide derived from thymidylate synthase having immunological and anti-tumour activity
08/24/2006	CA2598239A1 Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
08/24/2006	CA2598090A1 Synergistic effect of tgf-beta blockade and immunogenic agents on tumors
08/24/2006	CA2598076A1 Chemical compounds
08/24/2006	CA2598017A1 Triazole derivatives
08/24/2006	CA2597933A1 Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody
08/24/2006	CA2597813A1 Chemical compounds
08/24/2006	CA2597795A1 A molecule and chimeric molecules thereof
08/24/2006	CA2596015A1 Fused heterocyclic compounds useful as inhibitors of histone deacetylase
08/24/2006	CA2572151A1 Oligonucleotides comprising a non-phosphate backbone linkage
08/23/2006	EP1693457A2 Metastatic breast and colon cancer regulated genes
08/23/2006	EP1693456A1 Gene encoding g protein-coupled receptor and gene product thereof
08/23/2006	EP1693448A1 Double specific antibodies substituting for functional protein

1 ... 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 ... 2211